相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma
Tim J. Peterson et al.
ANNALS OF PHARMACOTHERAPY (2020)
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan et al.
DRUG RESISTANCE UPDATES (2020)
IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition
Yue Peng et al.
LIFE SCIENCES (2020)
NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma
Jiliang Xia et al.
MOLECULAR ONCOLOGY (2020)
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
Bojana Borjan et al.
FRONTIERS IN ONCOLOGY (2020)
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells
Daniele Tibullo et al.
BIOMOLECULES (2020)
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma
Shambavi Richard et al.
FUTURE ONCOLOGY (2020)
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Santiago Barrio et al.
LEUKEMIA (2019)
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Neeraj Gupta et al.
CLINICAL PHARMACOKINETICS (2019)
Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines
Mariana B. de Oliveira et al.
CURRENT MOLECULAR MEDICINE (2019)
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
Shannon M. Matulis et al.
LEUKEMIA (2019)
Emerging drug development technologies targeting ubiquitination for cancer therapeutics
Gianluca Veggiani et al.
PHARMACOLOGY & THERAPEUTICS (2019)
LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p
Yafang Pan et al.
CELL DEATH & DISEASE (2019)
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
Andrzej J. Jakubowiak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Blockade of SDF-1/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6
Ying Liu et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Carfilzomib for relapsed and refractory multiple myeloma
K. Groen et al.
CANCER MANAGEMENT AND RESEARCH (2019)
MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
Fang- Huang et al.
FRONTIERS IN ONCOLOGY (2019)
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma
Phyllis S. Y. Chong et al.
CANCER RESEARCH (2019)
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
Ola Landgren et al.
LEUKEMIA (2019)
The impact of the bone marrow microenvironment on multiple myeloma
Jianhao Hou et al.
ONCOLOGY REPORTS (2019)
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression
Sourav Banerjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma
Hiroshi Handa et al.
CANCERS (2019)
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
David Vrabel et al.
BLOOD REVIEWS (2019)
Structure of hRpn10 Bound to UBQLN2 UBL Illustrates Basis for Complementarity between Shuttle Factors and Substrates at the Proteasome
Xiang Chen et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
A. Besse et al.
LEUKEMIA (2018)
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
p62 filaments capture and present ubiquitinated cargos for autophagy
Gabriele Zaffagnini et al.
EMBO JOURNAL (2018)
Proteasome inhibitors for multiple myeloma
Kiyoshi Okazuka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Novel biomarkers in multiple myeloma
Adam Levin et al.
TRANSLATIONAL RESEARCH (2018)
Structure and Function of the 26S Proteasome
Jared A. M. Bard et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 87 (2018)
Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016
Andrew J. Cowan et al.
JAMA ONCOLOGY (2018)
Targeting Bcl-2 for the treatment of multiple myeloma
Cyrille Touzeau et al.
LEUKEMIA (2018)
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Nizar J. Bahlis et al.
BLOOD (2018)
Ixazomib for the treatment of multiple myeloma
Paul G. Richardson et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers
Peter Tsvetkov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Chang-Xin Shi et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance
Y. Song et al.
ONCOGENE (2017)
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L. Rasche et al.
NATURE COMMUNICATIONS (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Esther A. Zaal et al.
CANCER & METABOLISM (2017)
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells
Deepika Sharma Das et al.
CLINICAL CANCER RESEARCH (2017)
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
CLINICAL CANCER RESEARCH (2017)
Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma
Elisabeth Hoering et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma
Venera Kuci Emruli et al.
BMC CANCER (2016)
Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis
Patricia Gomez-Bougie et al.
CANCER LETTERS (2016)
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Andrew J. Yee et al.
LANCET ONCOLOGY (2016)
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells
D. S. Das et al.
LEUKEMIA (2016)
Oxidative stress and proteasome inhibitors in multiple myeloma
Brittany C. Lipchick et al.
PHARMACOLOGICAL RESEARCH (2016)
NF-κB dysregulation in multiple myeloma
Geoffrey M. Matthews et al.
SEMINARS IN CANCER BIOLOGY (2016)
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming
Irene Riz et al.
ONCOTARGET (2016)
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells
Enrico Milan et al.
AUTOPHAGY (2015)
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
Yuko Mishima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models
Irene Riz et al.
ONCOTARGET (2015)
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
Diego Acosta-Alvear et al.
ELIFE (2015)
Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents
Joel G. Turner et al.
SEMINARS IN CANCER BIOLOGY (2014)
The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells
Mohamed-Amine Hamouda et al.
ONCOTARGET (2014)
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Oliver D. K. Maddocks et al.
NATURE (2013)
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78
Gael Roue et al.
BLOOD (2011)
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
Shuqing Lue et al.
EXPERIMENTAL HEMATOLOGY (2009)
分享论文
